What is a stock summary page? Click here for an overview.
Business Description
Nymox Pharmaceutical Corp
NAICS : 325412
SIC : 2835
ISIN : BSP733981026
Description
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -10.09 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -528.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 15.4 | |||||
| 3-Year EPS without NRI Growth Rate | 16 | |||||
| 3-Year FCF Growth Rate | 31.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.07 | |||||
| 9-Day RSI | 63.7 | |||||
| 14-Day RSI | 60.7 | |||||
| 3-1 Month Momentum % | -9.9 | |||||
| 6-1 Month Momentum % | -24.92 | |||||
| 12-1 Month Momentum % | -76.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.09 | |||||
| Quick Ratio | 0.09 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 110160 | |||||
| Net Margin % | 120540 | |||||
| FCF Margin % | 81200 | |||||
| ROA % | -941.72 | |||||
| ROIC % | -488.15 | |||||
| 3-Year ROIIC % | 3091.74 | |||||
| ROC (Joel Greenblatt) % | -99016.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.35 | |||||
| EV-to-EBITDA | -2.35 | |||||
| EV-to-Revenue | -2788.6 | |||||
| EV-to-FCF | -3.18 | |||||
| Earnings Yield (Greenblatt) % | -42.55 | |||||
| FCF Yield % | -31.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NYMXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nymox Pharmaceutical Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -0.005 | ||
| EPS (TTM) ($) | -0.07 | ||
| Beta | 21.06 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 58.17 | ||
| Volatility % | 17040.25 | ||
| 14-Day RSI | 60.7 | ||
| 14-Day ATR ($) | 0.016375 | ||
| 20-Day SMA ($) | 0.110864 | ||
| 12-1 Month Momentum % | -76.29 | ||
| 52-Week Range ($) | 0.0001 - 1.4 | ||
| Shares Outstanding (Mil) | 93.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nymox Pharmaceutical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nymox Pharmaceutical Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nymox Pharmaceutical Corp Frequently Asked Questions
What is Nymox Pharmaceutical Corp(NYMXF)'s stock price today?
The current price of NYMXF is $0.14. The 52 week high of NYMXF is $1.40 and 52 week low is $0.00.
When is next earnings date of Nymox Pharmaceutical Corp(NYMXF)?
The next earnings date of Nymox Pharmaceutical Corp(NYMXF) is 2025-05-30 Est..
Does Nymox Pharmaceutical Corp(NYMXF) pay dividends? If so, how much?
Nymox Pharmaceutical Corp(NYMXF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers